Search the Newsreel

AVTX|Avalo Therapeutics Inc|Price:18.210|Chg%:+0.450

Avalo Therapeutics Inc. (AVTX) is a clinical-stage biotechnology company focusing on immune dysregulation, with its lead asset AVTX-009 targeting inflammatory diseases like hidradenitis suppurativa. The company exhibits stable fundamentals, high growth potential, and is considered fairly valued by analysts, with a strong buy rating …

Cantor Fitzgerald reiterates Avalo Therapeutics stock rating

Cantor Fitzgerald has reiterated an Overweight rating on Avalo Therapeutics (NASDAQ:AVTX), with the stock having surged 168% over the past year. The firm's analysis focused on Avalo's abdakibart (IL-1b) Phase 2 data and the upcoming Phase 3 trial for hidradenitis suppurativa, alongside implications from …

Avalo Therapeutics to Participate in the BTIG Biotechnology Conference

Avalo Therapeutics, a clinical-stage biotechnology company, announced that its CEO, Dr. Garry Neil, will participate in a panel discussion at the virtual BTIG Biotechnology Conference on July 29, 2026. Management will also hold one-on-one investor meetings. The company is focused on developing therapeutics targeting …

Avalo CEO to Participate in Virtual Hidradenitis Panel July 29

Avalo Therapeutics (Nasdaq: AVTX) announced that CEO Dr. Garry Neil will participate in the "Honing in on Hidradenitis" panel at the virtual BTIG Biotechnology Conference on July 29, 2026, at 10:30 a.m. ET. The company will also host one-on-one investor meetings. Avalo is focused …

Avalo Therapeutics Rings the Nasdaq Stock Market Closing Bell

Avalo Therapeutics (Nasdaq: AVTX), a clinical-stage biotechnology company, visited the Nasdaq MarketSite in Times Square to ring the Closing Bell. The ceremony honored the company's dedication to developing therapeutics for immune-mediated inflammatory diseases. Garry A. Neil, MD, Chief Executive Officer, had the honor of …

Avalo Therapeutics (NASDAQ:AVTX) Stock Price Down 5.4% - Here's What Happened

Avalo Therapeutics Says Some Shareholders May Sell Up to 128,189 Shares

Avalo Therapeutics announced that certain shareholders might sell up to 128,189 shares of its common stock. This potential sale is detailed in a regulatory filing the company recently submitted.

Form S-3 Avalo Therapeutics Inc For: 17 July By Investing.com

This article reports on the filing of Form S-3 by Avalo Therapeutics Inc. on July 17. The brief report, published by Investing.com, indicates the date of the SEC filing for the company.

Avalo Therapeutics (NASDAQ: AVTX) files to register 128,189 shares for selling stockholders

Avalo Therapeutics (NASDAQ: AVTX) has filed an S-3 registration statement to allow selling stockholders to resell up to 128,189 common shares. These shares were issued to former AlmataBio, Inc. stockholders as part of a Milestone Buyout Option Agreement. Avalo will not receive any proceeds …

Avalo Therapeutics (NASDAQ:AVTX) Trading 6.2% Higher - Here's Why

Avalo Therapeutics (Nasdaq:AVTX) - Stock Analysis

This Simply Wall St analysis provides a detailed look at Avalo Therapeutics (AVTX), a clinical-stage biotechnology company. It covers the company's financial health, market performance, and recent developments, including the appointment of Ron Philip to its Board of Directors and the advancement of its …

(AVTX) as a Liquidity Pulse for Institutional Tactics

This article analyzes Avalo Therapeutics Inc. (NASDAQ: AVTX), noting weak near-term sentiment but strong mid- and long-term outlooks. It identifies a significant 89.4:1 risk-reward setup, targeting a 24.6% gain, and provides three AI-generated trading strategies: Position Trading, Momentum Breakout, and Risk Hedging, tailored for …